

Press Release April 2023

mediproCan Pharma GmbH enters the market with premium product line "Jewel"

Neumünster, April 2023 - The GMP and GDP certified pharmaceutical company mediproCan Pharma GmbH, producer of medicinal cannabis, enters the market directly with high quality and exclusive cannabis flowers. The first selected strain is available immediately. From mid-May and August onwards, further premium strains will follow, which will be available on the German market with different THC contents.

The premium varieties are sourced both from Europe and from third countries. All partner producers comply with the EU GMP guidelines (European Good Manufacturing Practice) and have been qualified by mediproCan Pharma GmbH.

CEO Felix Kühl explains that the varieties marketed under the "Jewel" product line have been very selectively chosen and will be available to self-pay and statutory health insurance patients. The strains are intended to give alternatives to the therapies currently available on the market: *"Improving the quality of life of patients and supporting those people who are looking for an alternative, effective medical therapy for their disease - that is our mission."*

About mediproCan Pharma GmbH

mediproCan Pharma GmbH is a GDP and GMP certified pharmaceutical manufacturer of medical cannabis based in Neumünster, Schleswig-Holstein, Germany. mediproCan has been working hard over the past years to obtain all permits for import, trade and release of medical cannabis products and to build global partnerships with leading cannabis producers. The "Jewel" product line is mediproCan's first own product line, and the company also distributes classic strains from the Netherlands. Highest quality and constant availability are the clear set goals of the young but well-positioned company from Schleswig-Holstein. And whoever thinks they are new and inexperienced is mistaken. mediproCan is starting out with a highly professional team of experts who have decades of experience in the pharmaceutical industry and excellent knowledge of the cannabis industry.

For more information, please visit www.mediprocan.com.

Press contact
mediproCan Pharma GmbH
E-mail: presse@mediprocan.com